CML and Future Perspective. Hani Al-Hashmi, MD
|
|
- Baldwin Chapman
- 5 years ago
- Views:
Transcription
1 CML and Future Perspective Hani Al-Hashmi, MD
2 Objectives Learning from CML history Outcome of interest to clinician Patient and community interest!!
3 Learning from CML history
4 Survival Probability (All Ph+ CML Disease Phases) Imatinib Changed the Therapeutic Landscape for Patients With Ph+ CML , IFN- or SCT , imatinib* Best available therapy 5-Yr OS, % Imatinib* 93 IFN- or SCT + second-line imatinib 71 IFN- or SCT 63 IFN- 53 Hydroxyurea 46 Busulfan , IFN- or SCT plus second-line imatinib , IFN , hydroxyurea , busulfan Yrs After Diagnosis Leitner AA, et al. Internist (Berl). 2011;52:
5 Diagnosis of CML Hematologic Sensitivity Cytogenetic Molecular Karyotype (Ph chromosome) FISH PCR (BCR-ABL fusion) Peripheral blood (with myeloid cells) Bone marrow (with myeloid hyperplasia) Chromosomal translocation t(9;22)(q34;q11) Abnormal BCR-ABL Red: BCR Green: ABL Yellow: fusion Abnormal BCR-ABL Lane 1: BCR-ABL+ Lane 2: BCR-ABL-
6
7 Evolution of Treatment Goals Busulfan IFN Imatinib 2GTKI Best achievable response Complete Hematologic Response (CHR) Major Cytogenetic Response (CCyR) Major Molecular Response (MMR) Deeper Molecular Responses Tumor Reduction a 10% 1-log 1% 2-log Tumor Burden a Compared with baseline levels. CMR, complete molecular response; IFN, interferon; IS, international scale. CMR 4 and beyond 0.1% IS 3-log 0.01% IS 4-log % IS 4.5-log % IS 5-log Discontinuation?
8
9 Probability of Survival BCR-ABL/ABL Cutoff ~ 10% IS at 3 Mos Predicts Survival BCR-ABL/ABL > 9.84% 8-yr OS: 56.9% BCR-ABL/ABL 9.84% 8-yr OS: 93.3% 0.4 P < Yrs From Onset of Imatinib Therapy Marin D, et al. J Clin Oncol. 2012;30:
10 First-line Treatment Milestones Have Evolved The European LeukemiaNet (ELN) recommendations for optimal responses have shifted to deeper responses 3 to 6 months earlier in treatment 2 Similarly, failure criteria occur 3 months earlier vs 2009 ELN recommendations 3 months 6 months 12 months 18 months Log reduction 2009 ELN 1 CHR a, mcyr b 1 BCR-ABL IS = 10% 2013 ELN 2 PCyR c and/or BCR-ABL IS 10% PCyR c CCyR d and/or BCR-ABL IS < 1% CCyR d 2 BCR-ABL IS = 1% MMR e MMR e Stable or improving MMR f 3 BCR-ABL IS = 0.1% a Platelet count < /L, WBC < /L, differential count without immature granulocytes, and < 5% basophils b 36% to 65% Ph+ metaphases c 1% to 35% Ph+ metaphases d No Ph+ metaphases e BCR-ABL IS 0.1% f BCR-ABL to ABL (or other housekeeping gene) ratio 0.1%. 4.5 BCR-ABL IS = % Baccarani M, et al. J Clin Oncol. 2009;27: Baccarani M, et al. Blood. 2013;122(6):
11 Baccarani et al, Blood 2013;122:
12 Patients with EMR at 3 months had improved OS and PFS and a higher probability of subsequent deeper response vs patients without EMR 5-Year OS 5-Year PFS MR4.5 by 5 Years Patients with EMR had improved OS at 5 years Patients with EMR had improved PFS at 5 years Patients with EMR had a higher probability of achieving MR4.5 by 5 years 96% 100% 82% 95% 100% 78% 100% 63% n = 233 n = 24 n = 234 n = 24 n = 234 n = 24 EMR EMR failure EMR EMR failure EMR EMR failure 8% Hochhaus A, et al. Leukemia. 2016; 30(5): (Suppl).
13
14
15
16
17 Fewer Progressions Menu Fewer patients progressed with Nilotinib vs imatinib in ENESTnd Six times as many patients progressed to AP/BC on imatinib than on Nilotinib Progressions On Core Treatment (6-year follow-up) a 2 (0.7%) TASIGNA PATIENTS PROGRESSED vs P = (4.2%) 6 Months 12 Months 18 Months 24 Months 3 Years 4 Years 5 Years 6 Years IMATINIB PATIENTS PROGRESSED a Progression to AP/BC events included progressions to AP/BC (excluding clonal evolution) or CML-related deaths occurring on core treatment. Kantarjian HM, et al. Lancet Oncol. 2011;12(9): ; Hochhaus A, et al. Leukemia. 2016; 30(5):
18 Fewer Progressions Menu Fewer patients progressed with Dasatinib vs Imatinib in DASISION No P-value was provided for the difference in progression rates with dasatinib vs imatinib in DASISION Progressions During Treatment (5-year follow-up) a 12 Months 24 Months 3 Years 4 Years 5 Years 8 (3%) DASATINIB PATIENTS PROGRESSED (n = 259) 15 (5.8%) IMATINIB PATIENTS PROGRESSED (n = 260) a Progression events included increasing white blood cells despite appropriate therapeutic management, loss of CHR, partial CyR or CCyR, progression to AP/BC, or death. vs Kantarjian HM, et al. New Engl J Med. 2010;362(24): ; Kantarjian HM, et al. Blood. 2012;119(5): ; Jabbour E, et al. Blood. 2014;123(4): ; Cortes J, et al. J Clin Oncol Jul 10;34(20):
19 Fewer Progressions Menu Progressions on imatinib in ENESTnd and DASISION Approximately 7% of patients progressed to AP/BC with imatinib in both studies ENESTnd: On-Study Progressions With Imatinib /283 (7%) PATIENTS PROGRESSED DASISION: On-Study Progressions With Imatinib /260 (7%) PATIENTS PROGRESSED 1 year 2 years 3 years 4 years 5 years 6 years 1 year 2 years 3 years 4 years 5 years Limitations: On-study Progressions with imatinib data come from different trials with different durations of follow-up. Progression was defined differently in each trial. No cross trial comparison can be made. Kantarjian HM, et al. Lancet Oncol. 2011;12(9): ; Hochhaus A, et al. Leukemia. 2016; 30(5): Kantarjian HM, et al. New Engl J Med. 2010;362(24): ; Kantarjian HM, et al. Blood. 2012;119(5): ; Jabbour E, et al. Blood. 2014;123(4): ; Cortes J, et al. J Clin Oncol Jul 10;34(20):
20 Goals of Therapy Prolong survival Prevent progression Time at Risk Quality of Life Reduce toxicities Cost smart Treatment Free Remission 1. Baccarani M, et al. Blood. 2013;122(6): ; 2. Hughes T, et al. Blood. 2016; 128 (1):17-23; Steegmann JL, et al. Leukemia (2016) 30,
21 Outcome of interest to clinician
22 Evidence based medicine More potent TKIs: Faster response Deeper response Lower risk for: Progression and transformation Mutations Signals toward better PFS and OS
23 Making the decision According to: Disease risk assessment Side Effect profile FDA and Saudi FDA approved.
24 Earlier Menu
25 Patient and community interest!!
26 Life long TKIs Therapy!!! Occurrence of chronic low-grade adverse events Impaired Quality of Life Risk of inadequate drug compliance and poorer clinical outcome Eliasson L et al., Leuk Res, 2011;35(5): Noens L et al., Blood, 2009;13: Marin DJ et al.,clin Oncol, 2010;28: Akker M van den et al., J Clin Epidemiol, 1998;51: Akker M van den et al.,eurj GenPract, 1996;14:65 70 Tasigna Prescription information; September 2015.Novartis Pharma GmbH Glivec Prescription information; May 2016.Novartis Pharma GmbH Bansal D et al.,pediatr Blood Cancer, 2012;59(3):481-4
27 Life long TKIs Therapy!!! Occurrence of chronic low-grade adverse events Impaired Quality of Life Risk of inadequate drug compliance and poorer clinical outcome Age-increasing incidence of multi-morbidity requires intake of several drugs, leading to a higher risk for medication interaction Eliasson L et al., Leuk Res, 2011;35(5): Noens L et al., Blood, 2009;13: Marin DJ et al.,clin Oncol, 2010;28: Akker M van den et al., J Clin Epidemiol, 1998;51: Akker M van den et al.,eurj GenPract, 1996;14:65 70 Tasigna Prescription information; September 2015.Novartis Pharma GmbH Glivec Prescription information; May 2016.Novartis Pharma GmbH Bansal D et al.,pediatr Blood Cancer, 2012;59(3):481-4
28 Life long TKIs Therapy!!! Occurrence of chronic low-grade adverse events Impaired Quality of Life Risk of inadequate drug compliance and poorer clinical outcome Age-increasing incidence of multi-morbidity requires intake of several drugs, leading to a higher risk for medication interaction No TKI during pregnancy and nursing Eliasson L et al., Leuk Res, 2011;35(5): Noens L et al., Blood, 2009;13: Marin DJ et al.,clin Oncol, 2010;28: Akker M van den et al., J Clin Epidemiol, 1998;51: Akker M van den et al.,eurj GenPract, 1996;14:65 70 Tasigna Prescription information; September 2015.Novartis Pharma GmbH Glivec Prescription information; May 2016.Novartis Pharma GmbH Bansal D et al.,pediatr Blood Cancer, 2012;59(3):481-4
29 Life long TKIs Therapy!!! Occurrence of chronic low-grade adverse events Impaired Quality of Life Risk of inadequate drug compliance and poorer clinical outcome Age-increasing incidence of multi-morbidity requires intake of several drugs, leading to a higher risk for medication interaction No TKI during pregnancy and nursing Negative impact on growth and development in children and adolescents Eliasson L et al., Leuk Res, 2011;35(5): Noens L et al., Blood, 2009;13: Marin DJ et al.,clin Oncol, 2010;28: Akker M van den et al., J Clin Epidemiol, 1998;51: Akker M van den et al.,eurj GenPract, 1996;14:65 70 Tasigna Prescription information; September 2015.Novartis Pharma GmbH Glivec Prescription information; May 2016.Novartis Pharma GmbH Bansal D et al.,pediatr Blood Cancer, 2012;59(3):481-4
30 Life long TKIs Therapy!!! Occurrence of chronic low-grade adverse events Impaired Quality of Life Risk of inadequate drug compliance and poorer clinical outcome Age-increasing incidence of multi-morbidity requires intake of several drugs, leading to a higher risk for medication interaction No TKI during pregnancy and nursing Negative impact on growth and development in children and adolescents Lifelong CML-therapy; Cost implications on the patient and the community Eliasson L et al., Leuk Res, 2011;35(5): Noens L et al., Blood, 2009;13: Marin DJ et al.,clin Oncol, 2010;28: Akker M van den et al., J Clin Epidemiol, 1998;51: Akker M van den et al.,eurj GenPract, 1996;14:65 70 Tasigna Prescription information; September 2015.Novartis Pharma GmbH Glivec Prescription information; May 2016.Novartis Pharma GmbH Bansal D et al.,pediatr Blood Cancer, 2012;59(3):481-4
31 TFR and QoL
32 Probability of MMR Probability of CMR Achieving Molecular Response Long-term Adherence to Imatinib Is Critical for Achieving Molecular Response 1.0 MMR Adherence > 90% (n = 64) Adherence 90% (n = 23) 1.0 CMR Adherence > 90% (n = 64) Adherence 90% (n = 23) 0.8 P < P = Mos Since Start of Imatinib Therapy Mos Since Start of Imatinib Therapy Marin D, et al. J Clin Oncol. 2010;28:
33
34 STIM1: Patients With Sustained Deep Molecular Responses on Imatinib Can Maintain TFR
35
36 Cost Saving Taking into account the cost of imatinib and the number of months without treatment. The Saving in STIM (1 & 2) = 8.6 millions
37 Patients included between May 2012 and December 2014
38 EURO-SKI: Molecular Relapse Free Survival (n= 750)
39 Univariate analysis for relapse free survival at 6 months Significant association Treatment duration with imatinib MR4 duration Duration of IFN pre-treatment No significant association Age Gender Depth of molecular response (MR4.5vs. not in MR4.5) any variable part of the Sokal, EURO, EUTOS or ELTS scores
40 ENEST freedom: Study Design
41 ENEST freedom: Kaplan-Meier Estimated Treatment-Free Survival
42 Nilotinib Results in Higher Rates of MR4.5 vs Imatinib
43 ENESTfreedom: Response to Nilotinib Re-initiation
44 Leukemia(2016)30, ; doi: /leu Hematology-2017-Mahon-102-9
45 TKI Discontinuation/TFR A Novel Treatment Milestone Multiple studies have consistently demonstrated the safety and feasibility of stopping treatment TKI discontinuation is an emerging goal of CML management and is happening right now Patient awareness of TFR has resulted in increasing need for who can appropriately discontinue TKI A sustained DMR and long-term TKI therapy seem to be necessary prior to attempting TFR
46 Are we ready for routine discontinuation? Treatment discontinuation may be considered in individual patients, if proper, high-quality, and certified monitoring can be ensured. Pre-requisites for safe stopping are: 1. Institutional requirements for safe supervision 2. Identification of typical BCR-ABL1 transcripts at diagnosis 3. At least 5 years of TKI therapy 4. Achievement of DMR (MR4 - MR4.5) 5. Stability of DMR (at least MR4) for at least 2 years
47
48 `
Stopping treatment how much we understand about mechanisms to stop successfully today, and where are the limits? Andreas Hochhaus
Stopping treatment how much we understand about mechanisms to stop successfully today, and where are the limits? Andreas Hochhaus Frankfurt I 27.5.2017 Aims of CML Therapy Leukemia cells >10 12 CHR 10
More informationELN Recommendations on treatment choice and response. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy
ELN Recommendations on treatment choice and response Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy ELN 2013 Response to Front-line Treatment Baseline 3 months 6 months OPTIMAL
More informationHOW I TREAT CML. 4. KONGRES HEMATOLOGOV IN TRANSFUZIOLOGOV SLOVENIJE Z MEDNARODNO UDELEŽBO Terme Olimia, Podčetrtek,
HOW I TREAT CML 4. KONGRES HEMATOLOGOV IN TRANSFUZIOLOGOV SLOVENIJE Z MEDNARODNO UDELEŽBO Terme Olimia, Podčetrtek, 12. - 14. april, 2012 Gianantonio Rosti Dpt of Hematology and Oncological Sciences S.
More informationGuidelines and real World: Management of CML in chronic and advanced phases. Carolina Pavlovsky. FUNDALEU May 2017 Frankfurt
Guidelines and real World: Management of CML in chronic and advanced phases Carolina Pavlovsky. FUNDALEU 26-28 May 217 Frankfurt Some Issues in CML 217 First Line treatment: Imatinib vs 2nd generation
More informationMolecular monitoring of CML patients
EHA, Education Session, CML Stockholm, 14 June 2013 Molecular monitoring of CML patients Martin C. Müller Medical Faculty Mannheim Ruprecht-Karls-University Heidelberg Mannheim, Germany Disclosures Research
More informationCML: Living with a Chronic Disease
CML: Living with a Chronic Disease Jorge Cortes, MD Chief, CML and AML Sections Department of Leukemia M. D. Anderson Cancer Center Houston, Texas Survival in Early Chronic Phase CML TKI Interferon Chemotherapy
More informationA 34-year old women came because of abdominal discomfort. Vital sign was stable. Spleen tip was palpable.
1 Case 1 A 34-year old women came because of abdominal discomfort. Vital sign was stable. Spleen tip was palpable. CBC and bone marrow aspiration and biopsy were done. Chromosome study showed she had t(9;22)
More informationRole of Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed CML. GIUSEPPE SAGLIO, MD University of Torino, Italy
Role of Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed CML GIUSEPPE SAGLIO, MD University of Torino, Italy Outcome in 282 Patients Treated with Imatinib First Line in Hammersmith Hospital
More informationI nuovi guariti? La malattia minima residua nella leucemia mieloide cronica. Fabrizio Pane
I nuovi guariti? La malattia minima residua nella leucemia mieloide cronica Fabrizio Pane What could be the concept of Cure in CML? Sustained DMR with or without TKI therapy And 100% CML-related survival
More information2nd generation TKIs to first line therapy
New Horizons 2011 Newly diagnosed CML moving 2nd generation TKIs to first line therapy Gianantonio Rosti Dept. Of Hematology and Oncology St. Orsola-Malpighi University Hospital Bologna (Italy) GIMEMA
More informationEUROPEAN LEUKEMIANET RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA
EUROPEAN LEUKEMIANET RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA SAN DIEGO, 11 DECEMBER 2011 AMSTERDAM, 14 JUNE 2012 BALTIMORE, 20 SEPTEMBER 2012 ATLANTA, 6 DECEMBER 2012 ELN, CML Panel Jane Apperley
More informationThe concept of TFR (Treatment Free Remission) in CML
The concept of TFR (Treatment Free Remission) in CML Giuseppe Saglio University of Turin, Italy What can we expect today on long-term therapy with TKIs in CML? German CML study IV Relative and overall
More informationThe BCR-ABL1 fusion. Epidemiology. At the center of advances in hematology and molecular medicine
At the center of advances in hematology and molecular medicine Philadelphia chromosome-positive chronic myeloid leukemia Robert E. Richard MD PhD rrichard@uw.edu robert.richard@va.gov Philadelphia chromosome
More informationDoes Generic Imatinib Change the Treatment Approach in CML?
Does Generic Imatinib Change the Treatment Approach in CML? Jerald P. Radich, MD Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance NCCN.org For Clinicians NCCN.org/patients For Patients
More information2 nd Generation TKI Frontline Therapy in CML
2 nd Generation TKI Frontline Therapy in CML Elias Jabbour, M.D. April 212 New York Frontline Therapy of CML in 212 - imatinib 4 mg daily - nilotinib 3 mg BID - dasatinib 1 mg daily Second / third line
More informationChronic Myeloid Leukemia A Disease of Young at Heart but Not of Body
Chronic Myeloid Leukemia A Disease of Young at Heart but Not of Body Jeffrey H Lipton, PhD MD FRCPC Staff Physician, Princess Margaret Cancer Centre Professor of Medicine University of Toronto POGO November,
More informationLa terapia della LMC: è possibile guarire senza trapianto? Fabrizio Pane
La terapia della LMC: è possibile guarire senza trapianto? Fabrizio Pane What could be the concept of Cure in CML? Sustained DMR with or without TKI therapy And 100% CML-related survival And QoL comparable
More informationChronic Myeloid Leukaemia
Chronic Myeloid Leukaemia Molecular Response: What is really important? Jeff Szer The Royal Melbourne Hospital PROBABILITY, % PROBABILITY OF SURVIVAL AFTER MYELOABLATIVE TRANSPLANTS FOR CML IN CHRONIC
More informationJuan Luis Steegmann Hospital de la Princesa. Madrid. JL Steegmann
Juan Luis Steegmann Hospital de la Princesa. Madrid. Juan Luis Steegmann Hospital de la Princesa. Madrid No rush,at least in Chronic Phase Blast Phase*: SCT asap, after restablishing CP with TKI Accelerated
More informationHow I treat high risck CML
Torino, September 14, 2018 How I treat high risck CML Patrizia Pregno Hematology Dept. Citta della Salute e della Scienza Torino Disclosures Advisory Board: Novartis, Pfizer, Incyte Speaker Honoraria:
More informationIRIS 8-Year Update. Management of TKI Resistance Will KD mutations matter? Sustained CCyR on study. 37% Unacceptable Outcome 17% 53% 15%
Management of TKI Resistance Will KD mutations matter? IRIS 8-Year Update 17% 53% 5% 15% 37% Unacceptable Outcome No CCyR Lost CCyR CCyR Other 3% 7% Safety Lost-regained CCyR Sustained CCyR on study Deininger
More informationStarting & stopping therapy in Chronic Myeloid Leukemia: What more is needed? Richard A. Larson, MD University of Chicago March 2019
Starting & stopping therapy in Chronic Myeloid Leukemia: What more is needed? Richard A. Larson, MD University of Chicago March 2019 Disclosures Richard A. Larson, MD Research funding to the University
More informationWhat is the optimal management strategy for younger CP-CML patients with matched, related donors who fail to achieve CCyR
What is the optimal management strategy for younger CP-CML patients with matched, related donors who fail to achieve CCyR after 18 months of imatinib? Second generation TKIs as a bridge to allogeneic SCT
More informationDati sulla sospensione della terapia
Leucemia Mieloide Cronica Dati sulla sospensione della terapia Gianantonio Rosti, Bologna BCR-ABL Loading in CML Patients 100% 10% 1% MMR MR 4 MR 4.5 STIM study design N=100 Start Imatinib CMR Sustained
More informationOxford Style Debate on STOPPING Treatment.
Oxford Style Debate on STOPPING Treatment. This house believes that there are good reasons NOT to stop CML treatment. It should be done within clinical trials, OR only in expert centers where frequent,
More informationStopping Treatment in CML and dose reduction in clinical practice: Can we do it safely? YES WE CAN!
Stopping Treatment in CML and dose reduction in clinical practice: Can we do it safely? YES WE CAN! Dragana Milojković The Hammersmith Hospital, London, UK Leukemic burden Current Aim of TKI therapy Molecular
More informationRESEARCH ARTICLE. Introduction. Methods Wiley Periodicals, Inc.
BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase AJH Dennis (Dong Hwan) Kim, 1 * Nada Hamad,
More informationStopping TKI s in CML- Are we There Yet? Joseph O. Moore, MD Duke Cancer Institute
Stopping TKI s in CML- Are we There Yet? Joseph O. Moore, MD Duke Cancer Institute Natural History of CML Accumulation of immature myeloid cells New cytogenetic changes Chronic Phase Accelerated Phase
More information10 YEARS EXPERIENCE OF TYROSINE KINASE INHIBITOR THERAPY FOR CML IN OXFORD
10 YEARS EXPERIENCE OF TYROSINE KINASE INHIBITOR THERAPY FOR CML IN OXFORD Dalia Khan 1, Noemi Roy 1, Vasha Bari 1, Grant Vallance 1, Helene Dreau 1, Timothy Littlewood 1, Andrew Peniket 1, Paresh Vyas
More informationNEW DRUGS IN HEMATOLOGY
NEW DRUGS IN HEMATOLOGY BOLOGNA, 15-17 April 2013 TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKEMIA MICHELE BACCARANI michele.baccarani@unibo.it Historic Development of CML Therapy Palliative Therapy
More informationContemporary and Future Approaches in CML. Emory Meeting; Sea Island August 2014 Hagop Kantarjian, M.D.
Contemporary and Future Approaches in CML Emory Meeting; Sea Island August 2014 Hagop Kantarjian, M.D. 1 CML. Historical vs. Modern Perspective Parameter Historical Modern Course Fatal Indolent Prognosis
More informationCML HORIZONS 101 AND CML 101
CML HORIZONS 101 AND CML 101 by Pat Garcia-Gonzalez, USA May 1, 2015 Barcelona, Spain Goals of this Session Everything you ever wanted to know and were afraid of asking Help you navigate the conference
More informationBlast Phase Chronic Myelogenous Leukemia
Blast Phase Chronic Myelogenous Leukemia Benjamin Powers, MD; and Suman Kambhampati, MD The dramatic improvement in survival with tyrosine kinase inhibitors has not been demonstrated in the advanced blast
More informationMilestones and Monitoring
Curr Hematol Malig Rep (2015) 10:167 172 DOI 10.1007/s11899-015-0258-1 CHRONIC MYELOID LEUKEMIAS (E JABBOUR, SECTION EDITOR) Milestones and Monitoring Alessandro Morotti 1 & Carmen Fava 1 & Giuseppe Saglio
More informationCML 301 SOME INTRODUCTION INTO CML, CML SCIENCE, DRUG DEVELOPMENT AND INFORMATION RESOURCES. by Sarunas Narbutas Jan Geissler.
CML 301 SOME INTRODUCTION INTO CML, CML SCIENCE, DRUG DEVELOPMENT AND INFORMATION RESOURCES by Sarunas Narbutas Jan Geissler 4 May 2018 CML 101 / BASICS: UNDERSTANDING THE DISCUSSIONS IN CML SESSIONS What
More informationMRD in CML (BCR-ABL1)
MRD in CML (BCR-ABL1) Moleculaire Biologie en Cytometrie cursus Barbara Denys LAbo Hematologie UZ Gent 6 mei 2011 2008 Universitair Ziekenhuis Gent 1 Myeloproliferative Neoplasms o WHO classification 2008:
More informationContemporary and Future Approaches in Management of CML. Disclosures
Winship Cancer Institute of Emory University Contemporary and Future Approaches in Management of CML Hagop Kantarjian, MD Chairman and Professor, Department of Leukemia University of Texas M. D. Anderson
More informationCML David L Porter, MD University of Pennsylvania Medical Center Abramson Cancer Center CML Current treatment options for CML
1 CML 2012 LLS Jan 26, 2012 David L Porter, MD University of Pennsylvania Medical Center Abramson Cancer Center CML 2012 Current treatment options for CML patients Emerging therapies for CML treatment
More informationAccepted Manuscript. Improving Outcomes in Chronic Myeloid Leukemia Over Time in the Era of Tyrosine Kinase Inhibitors. Pradnya Chopade, Luke P.
Accepted Manuscript Improving Outcomes in Chronic Myeloid Leukemia Over Time in the Era of Tyrosine Kinase Inhibitors Pradnya Chopade, Luke P. Akard PII: S2152-2650(18)30343-4 DOI: 10.1016/j.clml.2018.06.029
More informationImplementation of Management Guidelines
Implementation of Management Guidelines For Chronic Myeloid Leukemia Perspectives in the United States David Rizzieri, MD; and Joseph O. Moore, MD ABSTRACT Clinical practice guidelines are developed to
More informationCurrent Monitoring for CML: Goals and. Jorge Cortes, MD Chief, CML & AML Section Department of Leukemia MD Anderson Cancer Center
Current Monitoring for CML: Goals and Principles Jorge Cortes, MD Chief, CML & AML Section Department of Leukemia MD Anderson Cancer Center Survival in Early Chronic Phase CML MDACC 2009 The Philadelphia
More information1 Educational session salient points. Tim Hughes, Vivian Oehler and Rick Van Etten. Tim - Imatinib is a less toxic drug than what we are seeing with
1 Educational session salient points. Tim Hughes, Vivian Oehler and Rick Van Etten. Tim - Imatinib is a less toxic drug than what we are seeing with both Nilotinib and Dasatinib. Nilotinib for the cardio
More informationTreatment free remission in CML: from the concept to practice. François-Xavier Mahon. Cancer Center Bordeaux Université Bordeaux, France
Treatment free remission in CML: from the concept to practice François-Xavier Mahon Cancer Center Bordeaux Université Bordeaux, France CML is a model 1960 1970 1980 1990 2000 2010 Philadelphia chromosome
More informationWhen to change therapy? Andreas Hochhaus Universitätsklinikum Jena, Germany
When to change therapy? Andreas Hochhaus Universitätsklinikum Jena, Germany Chromosome 22 Chromosome 9 e1 1b m-bcr M-bcr e1 e2 b1 b5 5 3 BCR ABL 5 3 1a a2 a3 μ -bcr e19 a11 e1a2 b2a2 b3a2 e19a2 p190 bcr-abl
More informationCML: definition. CML epidemiology. CML diagnosis. CML: peripheralbloodsmear. Cytogenetic abnormality of CML
MolecularDiagnostic.be Third Scientific Meeting Molecular Diagnostics.be t(9;22) CML: definition Management of CML patients treated with TKI: the place of molecular monitoring Antwerp, December 13 th 11
More informationForm 2012 R3.0: Chronic Myelogenous Leukemia (CML) Pre-Infusion Data
Form 2012 R3.0: Chronic Myelogeus Leukemia (CML) Pre-Infusion Data Key Fields Sequence Number: Date Received: - - CIBMTR Center Number: CIBMTR Research ID: Event date: - - HCT type: (check all that apply)
More informationCML: Role of combination treatments, Interferon and immunotherapy in CML
CML: 2017 Role of combination treatments, Interferon and immunotherapy in CML Andreas Burchert Philipps Universität Marburg Universitätsklinikum Gießen und Marburg GmbH Key Developments that will Change
More informationDiagnosis and Management of Chronic Myeloid Leukaemia
Diagnosis and Management of Chronic Myeloid Leukaemia Dr Simon Watt Dr Katherine O Neill Dr Fiona Dignan Written July 2017 Prof Tim Somervaille Review July 2019 1 Table of Contents 1.0 Introduction 3 2.0
More informationOutlook CML 2016: What is being done on the way to cure
New Horizons 2011 Outlook CML 2016: What is being done on the way to cure Gianantonio Rosti Dept. Of Hematology and Oncology St. Orsola-Malpighi University Hospital Bologna (Italy) GIMEMA CML Working Party
More informationAbstract. Research. Keywords: CML, Sokal score, Euro score, EUTOS score. Published: 06/10/2016 Received: 29/05/2016
Prognostic and predictive implications of Sokal, Euro and eutos scores in chronic myeloid leukaemia in the imatinib era experience from a tertiary oncology centre in Southern India Lakshmaiah Chinnagiriyappa
More informationCML: Yesterday, Today and Tomorrow. Jorge Cortes, MD Chief CML Section Department of Leukemia The University of Texas, M.D. Anderson Cancer Center
CML: Yesterday, Today and Tomorrow Jorge Cortes, MD Chief CML Section Department of Leukemia The University of Texas, M.D. Anderson Cancer Center Five Years of Signal Transduction Inhibition The Beginning
More informationDAVID S. SNYDER, M.D.
CML UPDATE 2019 DAVID S. SNYDER, M.D. MARCH 21,2019 Click to edit Master Presentation Date Disclosures I do not have anything to disclose 2001 2016 Loss in expectation of life of patients with chronic
More informationBMS Satellite Symposium
ICKSH 2018 BMS Satellite Symposium Emerging Trends in CML Management CHAIRMAN The Head of Catholic Hematology Hospital The Director of the Catholic Leukemia Research Institute at the Catholic University
More informationCHRONIC MYELOID LEUKEMIA (CML) Managing the Long and the Short of It
CHRONIC MYELOID LEUKEMIA (CML) Managing the Long and the Short of It Jeffrey H Lipton PhD MD Princess Margaret Cancer Centre Professor of Medicine University of Toronto CAGPO Annual Conference St. John
More informationNEW DRUGS IN HEMATOLOGY Bologna, 9-11 May 2016 CHRONIC MYELOID LEUKEMIA STATUS OF THE ART OF TREATMENT.
NEW DRUGS IN HEMATOLOGY Bologna, 9-11 May 2016 CHRONIC MYELOID LEUKEMIA STATUS OF THE ART OF TREATMENT Michele.baccarani@unibo.it Michele BACCARANI, MD Professor of Hematology at the Universities of Trieste,
More informationChronic myeloid leukemia (CML) Warunsuda Sripakdee, BCOP,BCP Prince of Songkla University
Chronic myeloid leukemia (CML) 1 Warunsuda Sripakdee, BCOP,BCP Prince of Songkla University Hematologic malignancies CML ALL AML 2 CML CD34+ results from an acquired mutation that affects hematopoietic
More informationWhat is New in CML in Hagop Kantarjian, M.D. February 2011
What is New in CML in 2011 Hagop Kantarjian, M.D. February 2011 1 CML. Historical vs. Modern Perspective Parameter Historical Modern Course Fatal Indolent Prognosis Poor Excellent 10-yr survival 10% 84-90%
More informationSESSION III: Chronic myeloid leukemia PONATINIB. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy
SESSION III: Chronic myeloid leukemia PONATINIB Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy Ponatinib A Pan-BCR-ABL Inhibitor Rationally designed inhibitor of BCR- ABL
More informationChronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring
Received: 13 December 2017 Accepted: 17 December 2017 DOI: 10.1002/ajh.25011 ANNUAL CLINICAL UPDATES IN HEMATOLOGICAL MALIGNANCIES Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring
More informationHistory of CML Treatment
History of CML Treatment Eduardo Olavarria No conflict of interest Lisbon, 20th March 2018 #EBMT18 www.ebmt.or What is CML? The mystery of chronic myeloid leukaemia Chronic myeloid leukaemia Often diagnosed
More informationManagement of CML in blast crisis. Lymphoma Tumor Board November 27, 2015
Management of CML in blast crisis Lymphoma Tumor Board November 27, 2015 Chronic Phase CML - 2. Peter Maslak, ASH Image Bank 2011; 2011-2455 Copyright 2011 American Society of Hematology. Copyright restrictions
More informationPatient With Chronic Myeloid Leukemia in Complete Cytogenetic Response: What Does It Mean, and What Does One Do Next?
VOLUME 32 NUMBER 5 FEBRUARY 10 2014 JOURNAL OF CLINICAL ONCOLOGY ONCOLOGY GRAND ROUNDS Patient With Chronic Myeloid Leukemia in Complete Cytogenetic Response: What Does It Mean, and What Does One Do Next?
More informationImatinib & Ponatinib. Two ends of the spectrum in 2016s reality
Imatinib & Ponatinib Two ends of the spectrum in 2016s reality CML 2016 Benefits & risks Steve O Brien CML Horizons, May 2016 Disclosures Research funding, participation in company trial, speaker, consultant,
More informationWhat is New in CML Jorge Cortes, MD Chief, CML and AML Sections Department of Leukemia MD Anderson Cancer Center Houston, Texas
What is New in CML 2018 Jorge Cortes, MD Chief, CML and AML Sections Department of Leukemia MD Anderson Cancer Center Houston, Texas Final Results CML-IV Molecular Response with Imatinib 1538 pts newly
More informationVenice Meeting Highlights: Key lessons. Conclusions Michele Baccarani Rüdiger Hehlmann
Venice Meeting Highlights: Key lessons Conclusions Michele Baccarani Rüdiger Hehlmann CML therapy in the imatinib era CML prognosis has improved dramatically Cellular and molecular biology studies help
More informationDeep molecular responses for treatment- free remission in chronic myeloid leukemia
Cancer Medicine REVIEW Open Access Deep molecular responses for treatment- free remission in chronic myeloid leukemia Stéphanie Dulucq 1 & Francois-Xavier Mahon 2 1 Laboratoire d Hématologie, Centre Hospitalier
More informationAGGIORNAMENTI IN EMATOLOGIA Faenza, 7 Giugno 2018 LMC: ALGORITMI TERAPEUTICI ATTUALI E IL PROBLEMA DELLA RESISTENZA.
AGGIORNAMENTI IN EMATOLOGIA Faenza, 7 Giugno 2018 LMC: ALGORITMI TERAPEUTICI ATTUALI E IL PROBLEMA DELLA RESISTENZA Michele.Baccarani@unibo.it EUROPEAN LEUKEMIANET 2013 (Blood 2013;122:885 892). RESPONSE
More informationDiscontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: What s Stopping us from Stopping?
Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: What s Stopping us from Stopping? David Pham, PharmD PGY2 Hematology/Oncology Pharmacy Resident South Texas VA Health Care System
More information1794 Updating Long-Term Outcome of Intermittent Imatinib. (INTERIM) Treatment in Elderly Patients with Ph+-CML
738 What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukaemia (CML) after Imatinib Loses Patent Exclusivity? https://ash.confex.com/ash/2014/webprogram/paper71699.html
More informationCML UPDATE 2018 DAVID S. SNYDER, M.D. MARCH
CML UPDATE 2018 DAVID S. SNYDER, M.D. MARCH 15, 2018 Click to edit Master Presentation Date DISCLOSURES I have nothing to disclose 2001 2016 Loss in expectation of life of patients with chronic myeloid
More informationWelcome and Introductions
Living with Chronic Myeloid Leukemia Welcome and Introductions Living with Chronic Myeloid Leukemia Living with Chronic Myeloid Leukemia (CML) Neil P. Shah, MD, PhD Edward S. Ageno Distinguished Professor
More informationResearch Article The Hasford Score May Predict Molecular Response in Chronic Myeloid Leukemia Patients: A Single Institution Experience
Disease Markers Volume 216, Article ID 7531472, 5 pages http://dx.doi.org/1.1155/216/7531472 Research Article The Hasford Score May Predict Molecular Response in Chronic Myeloid Leukemia Patients: A Single
More informationC Longer follow up on IRIS data
hronic Myeloid Leukemia Drs. Rena Buckstein, Mervat Mahrous & Eugenia Piliotis with input from Dr. J. Lipton (PMH) Updated August 2008* Updates: C Longer follow up on IRIS data Guidelines for monitoring
More informationCML Update 2016 Arthur 2016
CML Update 2016 Chronic Myeloid Leukemia Splenomegaly CML (3 phase disease) Increased white cells Malignant proliferation of myeloid white cells Initially mature cells a) chronic phase of disease Evolution
More informationMolecular Detection of BCR/ABL1 for the Diagnosis and Monitoring of CML
Molecular Detection of BCR/ABL1 for the Diagnosis and Monitoring of CML Imran Mirza, MD, MS, FRCPC Pathology & Laboratory Medicine Institute Sheikh Khalifa Medical City, Abu Dhabi, UAE. imirza@skmc.ae
More informationGreater Manchester and Cheshire Cancer Network Chronic Myeloid Leukaemia v3 2012
Greater Manchester and Cheshire Cancer Network Chronic Myeloid Leukaemia v3 2012 Dr Simon Watt Dr Shiva Natarajan 1.0 Introduction The landscape in chronic myeloid leukaemia (CML) has changed dramatically
More informationPost ASH Actualités LMC
Post ASH 2014 - Actualités LMC Actualités de première ligne LMC PC ENESTnd (6 ans) Dasision (5 ans) EPIC Spirit France (5 ans) Spirit 2 UK (5 ans) ENESTnd: Mise à jour à 6 ans Design = 846 ults with wly
More informationMolecular monitoring in CML and the prospects for treatment-free remissions
MANAGING TYPICAL AND ATYPICAL CHRONIC MYELOID LEUKEMIA Molecular monitoring in CML and the prospects for treatment-free remissions Michael W. Deininger 1,2 1 Huntsman Cancer Institute, The University of
More informationChronic Myeloid Leukemia: What more is needed? Richard A. Larson, MD University of Chicago March 2018
Chronic Myeloid Leukemia: What more is needed? Richard A. Larson, MD University of Chicago March 2018 Disclosures Richard A. Larson, MD Research funding to the University of Chicago: Astellas Celgene Daiichi
More informationOriginal Study. Abstract
Original Study The Effectiveness of Tyrosine Kinase Inhibitors and Molecular Monitoring Patterns in Newly Diagnosed Patients With Chronic Myeloid Leukemia in the Community Setting Nicholas J. Di Bella,
More informationA COMPARATIVE EFFECTIVENESS ANALYSIS OF PATIENTS NEWLY INITIATING TYROSINE KINASE INHIBITOR THERAPY FOR CHRONIC MYELOID LEUKEMIA.
A COMPARATIVE EFFECTIVENESS ANALYSIS OF PATIENTS NEWLY INITIATING TYROSINE KINASE INHIBITOR THERAPY FOR CHRONIC MYELOID LEUKEMIA Melea Ward A dissertation submitted to the faculty of the University of
More informationLow doses of tyrosine kinase inhibitors in CML
CML Horizons Conference Warsaw 4-6 May 2018 Low doses of tyrosine kinase inhibitors in CML Delphine Rea, MD, PhD Pôle Hématologie Oncologie Radiothérapie INSERM UMR-1160 Centre Hospitalo-Universitaire
More informationMolecular pathogenesis of CML: Recent insights
Napoli 24 gennaio 2012 Molecular pathogenesis of CML: Recent insights Giuseppe Saglio University of Turin CML Biology CML Clinical practice MILESTONES IN MOLECULAR BIOLOGY OF CML 1960 - Nowell P.C. & Hungerford
More informationShould nilotinib replace imatinib as first line treatment of chronic myeloid leukemia in chronic phase (CML-CP)?
Should nilotinib replace imatinib as first line treatment of chronic myeloid leukemia in chronic phase (CML-CP)? http://test.metromomsblog.org/wp-content/uploads/2010/02/tortoise-and-the-hare.jpg D. Van
More informationIs there a best TKI for chronic phase CML?
MANAGING TYPICAL AND ATYPICAL CHRONIC MYELOID LEUKEMIA Is there a best TKI for chronic phase CML? Richard A. Larson 1 1 Section of Hematology/Oncology, Department of Medicine, and Comprehensive Cancer
More informationPhiladelphia Positive (Ph+) Chronic Myeloid Leukaemia
Advocacy toolkit In this toolkit, we take a look into the treatments for Philadelphia-positive Chronic Myeloid Leukaemia (CML) that have led to treatment free remission (TFR) being one of the biggest topics
More informationWhat Can We Expect from Imatinib? CML Case Presentation. Presenter Disclosure Information. CML Case Presentation (cont)? Session 2: 8:15 AM - 9:00 AM
Welcome to Master Class for Oncologists Session 2: 8:15 AM - 9: AM Miami, FL December 18, 29 Chronic Myelocytic Leukemia: Imatinib and Beyond Speaker: Daniel J. DeAngelo, MD, PhD Dana-Farber Cancer Institute
More information9/26/2018. Learning Objectives
ADVANCES IN CHRONIC MYELOID LEUKEMIA Alison Wakoff Loren, MD, MSCE Associate Professor of Medicine Director, Blood & Marrow Transplantation Vice Chair, Faculty Development Department of Medicine Perelman
More informationMyeloproliferative Neoplasms
Myeloproliferative Neoplasms Judit Demeter CML chronic myeloid leukemia Semmelweis University, I st Department of Internal Medicine PV polycythaemia vera ET essential thrombocythaemia MF myelofibrosis
More informationDiscontinuation of Imatinib in Patients with Chronic Myeloid Leukemia Who Have Maintained Complete Molecular Response: Update Results of the STIM
Discontinuation of Imatinib in Patients with Chronic Myeloid Leukemia Who Have Maintained Complete Molecular Response: Update Results of the STIM François-Xavier Mahon, Delphine Réa, Joëlle Guilhot, François
More informationNew drugs and trials. Andreas Hochhaus
New drugs and trials. Andreas Hochhaus Hadera I Oct 2018 Introduction ABL001 is a potent, specific inhibitor of BCR-ABL1 with a distinct allosteric mechanism of action BCR-ABL1 Protein Binds a distinct
More informationRecent advances in the path toward the cure for chronic myeloid leukemia
VOLUME 46 ㆍ NUMBER 3 ㆍ September 2011 THE KOREAN JOURNAL OF HEMATOLOGY REVIEW ARTICLE Recent advances in the path toward the cure for chronic myeloid leukemia Dong-Wook Kim Department of Hematology, Seoul
More informationHorizon Scanning in Oncology
Horizon Scanning in Oncology Nilotinib (Tasigna ) for the 1 st -line treatment of Philadelphia chromosome positive chronic myeloid leukemia in the chronic phase DSD: Horizon Scanning in Oncology Nr. 15
More informationDETERMINANT VALUE OF THE CYTOGENETIC AND MOLECULAR IMATINIB THERAPEUTIC RESPONSE IN CHRONIC MYELOID LEUKEMIA
Analele Ştiinţifice ale Universităţii Alexandru Ioan Cuza, Secţiunea Genetică şi Biologie Moleculară, TOM XIV, 2013 DETERMINANT VALUE OF THE CYTOGENETIC AND MOLECULAR IMATINIB THERAPEUTIC RESPONSE IN CHRONIC
More informationGoals for chronic myeloid leukemia TK inhibitor treatment: how little disease is too much?
MINIMAL RESIDUAL DISEASE:CHRONIC MYELOID LEUKEMIA AND ACUTE LYMPHOCYTIC LEUKEMIA Goals for chronic myeloid leukemia TK inhibitor treatment: how little disease is too much? Michael J. Mauro 1 1 Memorial
More informationImatinib Mesylate in the Treatment of Chronic Myeloid Leukemia: A Local Experience
ORIGINAL ARTICLE Imatinib Mesylate in the Treatment of Chronic Myeloid Leukemia: A Local Experience PC Bee, MMed*, G G Gan, MRCP*, A Teh, FRCP**, A R Haris, MRCP* *Department of Medicine, Faculty of Medicine,
More informationNew drugs in first-line therapy
New drugs in first-line therapy Gianantonio Rosti Dept of Hematology and Oncology Seràgnoli, Bologna University (Italy) GIMEMA (Gruppo Italiano Malattie Ematologiche dell Adulto) CML WORKING PARTY IRIS
More informationState of the Art Therapy and Monitoring of CML Hagop Kantarjian, M.D. Grand Rounds UT Southwestern. October 28, 2010
State of the Art Therapy and Monitoring of CML - 2010 Hagop Kantarjian, M.D. Grand Rounds UT Southwestern October 28, 2010 1 CML. Historical vs. Modern Perspective Parameter Historical Modern Course Fatal
More informationChronic Myeloid Leukemia Outlook: The Future of CML Therapy
Chronic Myeloid Leukemia Outlook: The Future of CML Therapy Neil Shah, MD PhD Edward S. AgenoDistinguished Professor in Hematology/Oncology UCSF School of Medicine San Francisco, California Progression
More information15 th Annual Miami Cancer Meeting
15 th Annual Miami Cancer Meeting CLL and CML Mohamed A. Kharfan-Dabaja, MD, MBA, FACP Director, Blood and Marrow Transplantation and Cellular Therapies Mayo Clinic Jacksonville, FL 15 th Annual Miami
More information